Tevard Biosciences Presents Preclinical Data Showing Complete Dystrophin Restoration and Robust Titin Rescue with Suppressor tRNA Therapy at ASGCT 2026 Ready to Announce with Confidence?

Boston, Massachusetts--(Newsfile Corp. - May 14, 2026) - Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, will share new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. Tevard will present data demonstrating that its next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). The company will also present data showing that its novel sup-tRNAs provide durable rescue of full-length titin protein in a mouse model as well as functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

Click image above to view full announcement.

About Tevard Biosciences

Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The company's suppressor tRNA platform is designed to restore endogenous, full-length protein expression for diseases caused by premature termination codons. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders. For more information, visit www.tevard.com.

Contacts:

Michelle Linn

Linnden Communications

michelle@linndencom.com

Source: Tevard Biosciences

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297466

Source: Reportable, Inc.

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Reportable, Inc. or all companies in the Multimedia / Internet / Online Services industry.

Tevard Biosciences Presents Preclinical Data Showing Complete Dystrophin Restoration and Robust Titin Rescue with Suppressor tRNA Therapy at ASGCT 2026

2026-05-14 7:37 AM EDT

Stonegate Capital Partners Updates Coverage on Valens Semiconductor Ltd. (VLN) 1Q26

2026-05-13 4:21 PM EDT

Stonegate Capital Partners Updates Coverage On Surf Air Mobility Inc. (SRFM) 1Q26

2026-05-13 9:34 AM EDT

Dec 01, 2025

The year-end sprint is on. For your Investor Relations team, the time between now and the end of Q1 2026 will be packed with financial reporting, proxy statements, and regulatory filings.

Multimedia / Internet / Online Services